Cormorant Asset Management Reduces Stake in Bright Minds Biosciences Inc. to 9.71%

On April 30, 2026, Cormorant Asset Management, LP, filed a Schedule 13G/A with the SEC, reporting a decrease in its holdings of Bright Minds Biosciences Inc. (DRUG). As of the event date on April 28, 2026, the reporting persons, which include Cormorant Asset Management, LP and Bihua Chen, beneficially own 950,000 common shares. This represents a 9.71% ownership stake in the company, down from a previous position of 1,059,331 shares (10.88%). The shares are held directly by Cormorant Global Healthcare Master Fund, LP, for which Cormorant Asset Management serves as the investment manager and Bihua Chen serves as the managing member of the general partner. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The calculation of the ownership percentage is based on 9,787,161 common shares outstanding as of February 12, 2026.